Brain 17 Vienna

PROFILE trials

ALK+ advanced NSCLC

PROFILE 1005

PROFILE 1007

Phase II

randomise

730 patients

158 patients

Crizotinib

Crizotinib

chemotherapy

Brain metastases in patients with ALK-positive NSCLC

Costa et al 2015, J Clin Oncol; 33 (17): 1881-1888